MARKET

XLO

XLO

Xilio Therapeutics, Inc.
NASDAQ
0.5400
-0.0200
-3.57%
After Hours: 0.5800 +0.04 +7.41% 18:28 03/11 EDT
OPEN
0.5750
PREV CLOSE
0.5600
HIGH
0.5750
LOW
0.5373
VOLUME
279.40K
TURNOVER
--
52 WEEK HIGH
1.180
52 WEEK LOW
0.5030
MARKET CAP
39.67M
P/E (TTM)
-0.8218
1D
5D
1M
3M
1Y
5Y
1D
Xilio Therapeutics Updates Investor Presentation on I-O Strategy
TipRanks · 2d ago
Weekly Report: what happened at XLO last week (0302-0306)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 6d ago
Xilio Therapeutics announces inducement grants
TipRanks · 03/02 12:35
Xilio Therapeutics Grants Inducement Stock Options to New Employees
Reuters · 03/02 12:30
XILIO THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 03/02 12:30
Press Release: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 03/02 12:30
Weekly Report: what happened at XLO last week (0223-0227)?
Weekly Report · 03/02 09:04
More
About XLO
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.

Webull offers Xilio Therapeutics Inc stock information, including NASDAQ: XLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XLO stock methods without spending real money on the virtual paper trading platform.